Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From VertiFlex Inc.
Top 100 Review: The Calm Before The Storm – But Some Medtechs Already Reflect The Ravages Of COVID-19
2019 saw fewer revenues-boosting major acquisitions by top-tier medtechs. Companies that reported after the calendar year-end were the first to see the consequences of the pandemic on their annual figures.
Boston Scientific Buys Vertiflex For $465M To Add Minimally Invasive Lumbar Procedure
Vertiflex sells the Superion indirect decompression system, a minimally invasive device to treat lumbar spinal stenosis. Boston Scientific expects it to bring in $60m in revenue in 2019 to its Neuromodulation business.
Execs On The Move, August 2017
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Device/Diagnostics Quarterly Deal-Making Statistics, Q1 2017
Medtech companies brought in $2.3 billion in financing in Q1 2017, a slight decrease from Q4 2016; device M&A deals totaled $5.8 billion, a sharp decline from the prior quarter, but there were some billion-dollar deals. Q1 diagnostics financings – totaling $1.2 billion (thanks to a $900 million Series B round by cancer diagnostics company Grail) – showed a significant increase over the preceding quarter, as did the Q1 M&As at $700 million versus the previous $87 million.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.